Pricing Log in Create free account
Saturday 17 October 2026 Export CLNN’s income statement to Excel — free account

Clene Inc.

CLNN Healthcare Biotechnology

Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024. In the quarter to June 2026, revenue grew 233.3%, EPS fell 38.5%, free cash flow grew 45.4% and total debt rose 16.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.10 0.21 −6.34%
Market cap
$47.0M
P/E
0.0×
Fwd P/E
−3.1×
Dividend yield
—
F-score
2/9
Altman Z
−27.14
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.22
Total sells 5.78
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — 1 — — — — — — — — —
Sell — 5 7 1 2 5 2 — — — — —
Insider Ownership 8.58%

Capital & Financial Ratios $m

Market Cap 46.98
Revenue 0.20
Net Income (39.52)
Free Cash Flow (15.95)
Net Debt 8.64
Current Ratio 3.07 (at or above 1.5: strong)
Debt/Equity (0.74) (negative: negative equity)
P/E ratio 0.00
Fwd P/E (3.05) (negative: loss-making)
P/S ratio 194.86 (above 10: high)
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 2.87%
Next Y EPS Growth 41.88% (at or above 15%: strong)
Next Y revenue growth (81.33%) (below 0%: weak)
Next 5Y EPS Growth 65.56% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 239×, against a ten-year median of 207×; over the ten years it ranged from 18.2× in 2023 to 2,090× in 2021.
P/S against its own 10 years 48.18%
10-year low 10-year high
EV/Sales against its own 10 years 55.05%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 35 12 5 10
Receivables 0 0 — 0
Inventory 0 0 0 0
Other — — — —
39 16 9 15
2023 2024 2025 Q'26
Payables 2 1 1 1
ST’ Debt — — — —
Other — — — —
25 10 11 5

Compound Annual Growth %

10y 5y 3y
Sales — (0.59%) (24.94%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 0 0 0 0 0
’23 0 0 0 0 1
’22 0 0 0 0 0
’21 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (3) — — —
’25 (5) (5) (4) (5) (19)
’24 (7) (6) (3) (5) (21)
’23 (9) (7) (7) (7) (30)
’22 (13) (10) (8) (8) (39)
’21 (9) (9) (7) (10) (35)
’20 (3) (2) (8) (6) (19)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (3) — — —
’25 (5) (5) (4) (5) (19)
’24 (7) (6) (3) (5) (21)
’23 (9) (7) (7) (7) (31)
’22 (14) (11) (10) (9) (44)
’22 — — — — (39)
’21 (9) (9) (8) (10) (36)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.69) (1.08) — — —
’25 (0.09) (0.78) (0.85) (0.88) (2.65)
’24 (1.80) (1.06) (1.22) (1.67) (5.67)
’23 (3.00) (5.80) (0.40) (1.20) (9.40)
’22 (4.20) (1.40) (3.40) 0.00 (9.20)
’21 (13.20) (1.00) 8.40 1.40 (3.20)
’20 (4.54) (6.70) (11.86) 1.08 (22.00)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 193.00 198.00 206.00 75.60 17.40 5.00 3.82 2.28

Analyst estimates 2026–2028

Powerpack
High — — 199.00 210.00 350.00 356.40 102.60 39.80 11.00 13.50
People
People Employees — — — — 74 102 86 85 76 79
Revenue/emp, $m — — — — 0.00 0.01 0.01 0.01 0.00 0.00
Income, $m
Income, $m Revenue — — — — 0 1 0 1 0 0
Gross margin, % — — — 0.00 68.45 60.03 94.50 81.50 79.53 78.50
EBT — 0 0 (16) (19) (10) (30) (50) (39) (26)
EBT margin, % — 0.00 0.00 0.00 (9,160.68) (1,406.36) (6,325.16) (7,569.42) (11,520.47) (13,086.50)
Net income — 0 0 (16) (19) (10) (30) (50) (39) (26)
Depreciation — 0 — 1 1 1 1 2 2 1
Per share, $
Per share, $ Revenue — 0.00 0.00 0.00 0.24 0.23 0.15 0.12 0.05 0.02
Earnings — 0.00 (4.00) (18.61) (22.00) (3.20) (9.20) (9.40) (5.67) (2.65)
Cash flow — 0.00 (3.02) (15.21) (21.63) (11.25) (11.97) (5.75) (3.07) (1.88)
Capex — 0.00 0.00 (0.34) (0.44) (0.43) (1.59) (0.06) 0.00 0.00
Free cash flow — 0.00 (3.02) (15.54) (22.07) (11.68) (13.55) (5.81) (3.07) (1.89)
Book value — 0.00 73.64 (78.09) 0.39 4.09 0.99 2.55 (1.27) (1.78)
Shares, m — 2 0 1 1 3 3 5 7 10
Valuation, ×
Valuation, × P/E — — — — 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — — 919.38 349.08 130.96 46.53 107.97 289.36
P/B — — — — 555.41 20.04 19.14 2.27 0.00 0.00
EV/Sales — — — — 642.10 306.06 122.45 11.45 117.53 331.12
EV/FCF — — — — (6.85) (6.15) (1.31) (0.25) (1.88) (3.56)
Cash, $m
Cash, $m Operating cash flow — 0 0 (13) (19) (35) (39) (30) (21) (19)
Capex — 0 — 0 0 (1) (5) 0 0 0
Free cash flow — 0 0 (13) (19) (36) (44) (31) (21) (19)
Balance, $m
Balance, $m Working capital — 0 1 5 51 49 15 14 6 (2)
Total debt — — — 1 2 19 19 12 15 14
Net debt — — (1) (8) (57) (31) (4) (23) 3 8
Shareholders’ equity — 0 5 (68) 0 13 3 13 (9) (18)
Returns, %
Returns, % ROA — 0.00 (1.17) (52.08) (46.38) (14.84) (55.63) (102.25) (98.90) (115.13)
ROIC — 0.00 (4.76) 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE — 0.00 (11.10) 51.47 57.17 (150.56) (377.90) (595.47) (1,738.36) 197.91
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Clene Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HOWL Werewolf Therapeutics, Inc. $48.5M — (loss-making) — (loss-making) +256.11% (above 0%: growing) n/m +146.46% (above 0%: growing) 100.00% 34.09% Compare
ELTX Elicio Therapeutics, Inc. $48.2M — (loss-making) — (loss-making) −55.27% (below 0%: shrinking) n/m +8.77% (above 0%: growing) 0.00% 0.00% Compare
ACET Adicet Bio, Inc. $48.1M — (loss-making) — (loss-making) +727.73% (above 0%: growing) n/m +24.94% (above 0%: growing) 0.00% 0.00% Compare
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $47.6M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00% Compare
CLNN Clene Inc. $47.0M — (loss-making) — (loss-making) +233.33% (above 0%: growing) n/m +45.43% (above 0%: growing) 60.00% (5,941.11%)
TVGN Tevogen Inc. $46.1M — (loss-making) — — n/m +5.78% (above 0%: growing) — 0.00% Compare
INMB INmune Bio, Inc. $45.8M — (loss-making) — (loss-making) +8.70% (above 0%: growing) n/m +55.39% (above 0%: growing) 100.00% 0.00% Compare
IMA ImageneBio, Inc. $45.7M — (loss-making) — (loss-making) −60.08% (below 0%: shrinking) n/m +23.76% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $47.7M — — +54.35% — +17.84% 100.00% 0.00%

All 614 Biotechnology stocks →

Clene Inc. (CLNN) key facts

  • Concern: Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
  • Clene Inc. (CLNN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, CLNN traded at $3.10, a market capitalization of $47.0 million.
  • Return on equity was 197.9% and debt-to-equity -0.74.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −27.14 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Clene Inc. (CLNN) Latest News

4 May

Impact 5 ·
stockrow.com/CLNN · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com